Roxadustat treatment for anemia in 20 cases of patients undergoing initial-stage hemodialysis
Author(s): SUN Yan-ling, XIE Hua, KANG Zhe, ZHANG Sheng-kun, ZHAO Ting-ting, WANG Bo-wen, Dalian Renal Care Hospital
Pages: 942-946
Year: 2020 Issue: 11
Journal: Chinese Journal of Practical Internal Medicine
Keyword: initial-stage hemodialysis; renal anemia; Roxadustat; erythropoiesis stimulating agents;
Abstract: Objective To assess the effectiveness of roxadustat in the treatment of anemia in patients undergoing initialstage hemodialysis. Methods It was a retrospective cohort study conducted in a single center. Patients who underwent inital hemodialysis(≤4 months)from August 2019 to April 2020 Dalian Renal Care Hospital were enrolled in the study(n=40).Patients were divided into two groups roxadustat group and erythropoiesis～stimulating agents(ESA)group. The starting dose of roxadustat was either 70 mg or 100 mg according to the patients’ weight,which was taken orally 3 times a week after dialysis. The starting dose of ESA was 100 U/kg per week,which was given by intravenous injection after dialysis. The level of Hb,CRP and MAP at baseline and 2,4,12 and 24 weeks of treatment was observed. The primary end point was the mean change in hemoglobin level during 24 weeks.The secondary end points were the decline of CRP and the incidence rate of MACE and MACE+ in 24 weeks. Results There was no difference between two groups in age,gender,duration after initiation of hemodialysis,primary disease or the baseline hemoglobin level(P>0.05). Roxadustat led to a highter mean hemoglobin level at week 24 than ESA[(113.0±4.83)g/L vs.(106.0 ± 5.61)g/L,P<0.05)],and the mean change in hemoglobin level at week 2 was also significantly higher(P<0.01).As compared with ESA,roxadustat decreased the mean CRP at week 24[(12.8±13.97 mg/Lvs.(2.02±3.04)mg/L,P<0.05)]. In patients with CRP ≤10 mg/L,the compliance rate of hemoglobin ≥110 g/L in the roxadustat group was higher than that in the ESA group(95% vs. 60%,P<0.01). There was no difference in MAP between the two groups at each time point(P>0.05).One MACE+ occurred in the ESA group and none in the roxadustat group in 24 weeks. Conclusion Roxadustat has higher target rate,more quickly response and is not affected by inflammation.Roxadustat has advantage over ESA as therapy for anemia in patients undergoing initial-stage hemodialysis.
Pages: 942-946
Year: 2020 Issue: 11
Journal: Chinese Journal of Practical Internal Medicine
Keyword: initial-stage hemodialysis; renal anemia; Roxadustat; erythropoiesis stimulating agents;
Abstract: Objective To assess the effectiveness of roxadustat in the treatment of anemia in patients undergoing initialstage hemodialysis. Methods It was a retrospective cohort study conducted in a single center. Patients who underwent inital hemodialysis(≤4 months)from August 2019 to April 2020 Dalian Renal Care Hospital were enrolled in the study(n=40).Patients were divided into two groups roxadustat group and erythropoiesis～stimulating agents(ESA)group. The starting dose of roxadustat was either 70 mg or 100 mg according to the patients’ weight,which was taken orally 3 times a week after dialysis. The starting dose of ESA was 100 U/kg per week,which was given by intravenous injection after dialysis. The level of Hb,CRP and MAP at baseline and 2,4,12 and 24 weeks of treatment was observed. The primary end point was the mean change in hemoglobin level during 24 weeks.The secondary end points were the decline of CRP and the incidence rate of MACE and MACE+ in 24 weeks. Results There was no difference between two groups in age,gender,duration after initiation of hemodialysis,primary disease or the baseline hemoglobin level(P>0.05). Roxadustat led to a highter mean hemoglobin level at week 24 than ESA[(113.0±4.83)g/L vs.(106.0 ± 5.61)g/L,P<0.05)],and the mean change in hemoglobin level at week 2 was also significantly higher(P<0.01).As compared with ESA,roxadustat decreased the mean CRP at week 24[(12.8±13.97 mg/Lvs.(2.02±3.04)mg/L,P<0.05)]. In patients with CRP ≤10 mg/L,the compliance rate of hemoglobin ≥110 g/L in the roxadustat group was higher than that in the ESA group(95% vs. 60%,P<0.01). There was no difference in MAP between the two groups at each time point(P>0.05).One MACE+ occurred in the ESA group and none in the roxadustat group in 24 weeks. Conclusion Roxadustat has higher target rate,more quickly response and is not affected by inflammation.Roxadustat has advantage over ESA as therapy for anemia in patients undergoing initial-stage hemodialysis.
Related Articles